Palvella Therapeutics Inc (PVLA) saw downtrend of -4.09% in the recent trading with $99.73 being its most recent. The current price level -13.04% lower than the highest price of $114.69 marked by the stock while trading over the past 52-weeks, whereas it is 724.21% higher than the lowest price of $12.10 the company dropped to over past 52-weeks. The latest news story on PVLA appeared in (GlobeNewswire) under the title “Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Palvella Therapeutics Inc Earnings – What Happened With PVLA
Coming around sales and income figures on PVLA Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Palvella Therapeutics Inc (PVLA) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of -798.74% for net revenue.
PVLA – Palvella Therapeutics Inc Stock Earnings Estimates
The perspective of Palvella Therapeutics Inc (NASDAQ:PVLA),s current quarter earnings identifies that analysts are in consensus over the estimate of -0.6 for stock,s EPS in the current quarter. Palvella Therapeutics Inc (PVLA) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of -798.74% for net revenue. Company,s EPS for the last quarter was -5.37.
Palvella Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 11.09 million. PVLA does have institutional investors; and they hold 64.48% of the stock.
As on 2024-06-30, BVF INC/IL was the top most holder in Palvella Therapeutics Inc (NASDAQ:PVLA) with an ownership of 0.26 million shares of the company or 2.2959 of the stake worth $2.55 million. The filing also reveals LYNX1 CAPITAL MANAGEMENT LP as the second largest holder in the company with a control over 0.3877 of the outstanding shares. Its stake is worth $0.43 million for having 43499.0 shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 0.1156 of the outstanding shares. With this there are now 153.0 institutions which have possession in PVLA,s shares.
Key Metrics for PVLA
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Palvella Therapeutics Inc has a debt to equity ratio of 0.41.
